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C-reactive protein (CRP) binds with high affinity to
fibronectin (Fn), a major component of the extracellular
matrix (ECM), but at physiological pH the binding is
inhibited by calcium ions (Ca2ⴙ). Because CRP circulates in the blood in Ca2ⴙ-bound form, the occurrence of
CRP-Fn interactions in vivo has been doubtful. To define
the basis of inhibition of CRP-Fn interaction by Ca2ⴙ at
pH 7.0, we hypothesized that Fn-binding site on CRP
consisted of amino acids co-ordinating Ca2ⴙ. Site-directed mutagenesis of amino acids co-ordinating Ca2ⴙ
drastically decreased the binding of CRP to Fn, indicating that the Ca2ⴙ-binding site indeed formed the Fnbinding site. To determine the requirements for possible
interaction between Ca2ⴙ-bound CRP and Fn, we investigated inhibition of CRP-Fn interaction by Ca2ⴙ as a
function of pH. Ca2ⴙ did not inhibit binding of CRP to Fn
at pH 6.5 and lower. The contrasting Fn binding properties of CRP at physiological and mildly acidic pH indicated that the interaction of Ca2ⴙ-bound CRP with Fn
was controlled by pH. We conclude that the inhibition of
binding of CRP to Fn by Ca2ⴙ at pH 7.0 is a mechanism to
prevent CRP-Fn interactions under normal conditions.
CRP, in its Ca2ⴙ-bound state, is capable of binding Fn
but only at the inflammatory sites and tumors with low
pH. CRP, Fn, and the ECM all have been implicated in
cancer. Taken together our data raise the possibility
that CRP-Fn interactions may change the architecture
of ECM to modify the development of tumors.

C-reactive protein (CRP)1 is an evolutionarily conserved
plasma protein that is considered to be a multifunctional component of the acute phase response and innate host defense
system (1, 2). CRP has been shown to affect the results of the
experiments related to diverse pathologic states (3, 4) such as
bacterial infection (5, 6), atherosclerosis (7), autoimmune disease (8), and cancer (9). Most proposed functions of CRP depend
on its ability to recognize and bind substances of physiologic
value (10, 11). By virtue of its wide binding specificities, CRP
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1
The abbreviations used are: CRP, C-reactive protein; nCRP, native
CRP; Fn, fibronectin; PCh, phosphocholine; PnC, pneumococcal C-polysaccharide; ECM, extracellular matrix; WT, wild type; ELISA, enzyme-linked immunosorbent assay; TBS, Tris-buffered saline; mAb,
monoclonal antibody; BSA, bovine serum albumin.

gets deposited at sites of tissue damage and inflammation (12,
13). Two types of molecular contacts are known for the binding
of CRP to its ligands, one that requires calcium ions (Ca2⫹) and
another that does not require Ca2⫹ and instead is inhibited by
Ca2⫹ (2). The Ca2⫹-dependent ligands are primarily the phosphocholine (PCh)-containing substances such as C-polysaccharide (PnC) of the cell wall of Streptococcus pneumoniae (10),
modified low density lipoprotein (7, 14), and apoptotic cells (14,
15). Ca2⫹-independent ligands include polycations (16, 17) and
the extracellular matrix (ECM) protein fibronectin (Fn) (18,
19). In this paper we report the mechanism of CRP-Fn interactions and discuss their suitability for in vivo circumstances.
CRP is one of the pentraxin proteins composed of 5 identical
206-amino acid-long subunits (20, 21). All five subunits have
the same orientation in the pentamer, with a Ca2⫹-binding site
and a PCh-binding site located on the same face of each subunit
(2). Each Ca2⫹ site occupies two Ca2⫹. Using synthetic peptides
derived from CRP, direct binding of Ca2⫹ to a peptide of residues 134 –148 has been shown (22). Crystallography of
CRP䡠Ca2⫹䡠PCh complex (Fig. 1) has demonstrated that two
Ca2⫹ in CRP are co-ordinated by Asp-60, Asn-61, and by residues (Glu-138, Gln-139, Asp-140, Glu-147, and Gln-150) in a
loop (23–25). This loop in the absence of bound Ca2⫹ moves
away from the main body of the CRP molecule, exposing an
otherwise hidden site of proteolysis (26). Bound Ca2⫹ ions
protect CRP from proteolytic cleavage and are integral structural elements of CRP. It is believed that CRP circulates in the
body in its Ca2⫹-bound form.
Fn is a multifunctional glycoprotein present in the blood in
addition to being the major component of the ECM (27). Fn is
also highly expressed in several tumors (28 –30). Fn plays key
roles in cell adhesion and migration processes in various physiological events, such as wound healing, thrombosis, tissue
remodeling, and cancer (27, 28). Thus, understanding the nature of CRP-Fn interaction and its impact on each other’s
functions is of importance.
Some features of CRP-Fn interaction have been reported a
decade ago (10, 18, 19). CRP-Fn interaction does not require
Ca2⫹, and the maximal interaction occurs at pH 5.0. At physiological pH it has been shown that Ca2⫹ inhibits binding of
CRP to Fn (18). We hypothesized (31) that the Fn-binding site
consisted of amino acids in CRP that co-ordinated Ca2⫹. In the
present study our main goal was to define the mechanism of
CRP-Fn interactions so as to validate the occurrence of CRP-Fn
interactions in vivo. Our data indicated that the Ca2⫹ site of
CRP participated in binding to Fn and provided an explanation
for the inhibitory role of Ca2⫹ on CRP-Fn interaction. Furthermore, at pH 7.0 Ca2⫹ inhibited CRP-Fn interaction, whereas at
pH 6.5 and lower it did not. These findings support that in vivo
Ca2⫹-bound CRP has the capability of interacting with Fn but

52552
This is an Open Access article under the CC BY license.

This paper is available on line at http://www.jbc.org

Mechanism of CRP-Fibronectin Interactions in Vivo

FIG. 1. Ca2ⴙ-binding site of CRP. The ViewerPro 4.2 software
(Accelrys Inc.) was used to generate ribbon diagram of the crystal
structure of CRP䡠Ca2⫹䡠PCh complex (24) obtained from Brookhaven
Protein Data Bank. A portion of one of the five subunits is shown. The
side chains of seven amino acids co-ordinating two Ca2⫹ are highlighted. Ca2⫹ ions are in gray, and the PCh molecule is in orange.

exclusively at the ECM of the inflammatory sites including
carcinomas where the pH goes down.
EXPERIMENTAL PROCEDURES

Construction and Expression of CRP Mutants—We constructed CRP
cDNA encoding E138A, Q139A, D140A, E147A, E147Q, E147K, Q150A,
D60A, N61A, and D60A/E147A mutants. The WT human CRP cDNA in
the expression vector p91023 (32) was used as the template for construction of cDNA-encoding proteins with single amino acid substitutions. The D60A mutant CRP cDNA was used as a template to construct
cDNA for the D60A/E147A CRP. Site-directed mutagenesis was conducted using the QuikChange mutagenesis kit (Stratagene). Mutagenic
oligonucleotides (Fig. 2) were designed according to the kit instructions
and obtained from Integrated DNA Technologies. Mutations were verified by sequencing performed in our Core Facility. Two clones for each
mutant were purified using the maxiprep plasmid isolation kit (Eppendorf). COS cells were used for protein expression and cultured as
described previously (31). Cells (2 ⫻ 106) were transfected with 5 g of
the plasmids containing mutant CRP cDNA using FuGENE 6 (Roche
Applied Science). At 96 h post-transfection, culture media were collected, and the expression of CRP was determined by employing ELISA.
Purification of CRP—The WT native CRP (nCRP) was purified from
ascitic fluid, and WT recombinant CRP was purified from the culture
medium of the stable Chinese hamster ovary cell line (31) by three
steps, a Ca2⫹-dependent affinity chromatography on a PCh-Sepharose
column (Pierce) followed by an anion-exchange chromatography on a
Mono Q column and a gel filtration on a Superose12 column (GE
Healthcare) using the Biologic Duo Flow Protein Purification System
(Bio-Rad). Mutants of CRP were purified from culture media by affinity
chromatography alone as before (31). Briefly, culture media were
passed through the PCh-Sepharose in a Ca2⫹-containing buffer, and the
bound CRP was eluted with an EDTA-containing buffer. CRP-positive
fractions, identified by ELISA, were pooled and dialyzed against TBS
(10 mM Tris-HCl, pH 7.2, 150 mM NaCl).
CRP ELISA—The concentration of CRP was estimated using ELISA
(31). A polyclonal anti-CRP antibody (1/1000 dilution; Sigma) was used
as the capture antibody, and the affinity-purified anti-CRP mAb HD2.4
(0.5 g/ml) was used as the reporter. The HD2.4 mAb was affinitypurified from the cell culture supernatant of a hybridoma cell line
(ATCC). Standard curves were constructed with purified nCRP (3.13–
100 ng/ml) diluted in TBS, 0.1% gelatin, 0.01% Tween 20. Horseradish
peroxidase-conjugated goat anti-mouse IgG H⫹L (Pierce) was used as
the secondary antibody. Color was developed with 300 g/ml ABTS
chromophore, diammonium salt (Calbiochem), 0.03% H2O2 in 0.5 M
citrate buffer, pH 4.0, and measured at 405 nm in the microtiter plate
reader (Molecular Devices).
PCh Binding Assay—Binding activity of CRP for PCh-containing
ligands was evaluated by two assays using PCh-BSA (Biosearch Technologies) and PnC (Statens Seruminstitut) (31). Briefly, microtiter
wells were coated with either PCh-BSA (10 g/ml) or PnC (2 g/ml).
Culture media were diluted to appropriate concentrations in TBS-Ca
(TBS, 0.1% gelatin, 0.01% Tween 20, 5 mM CaCl2). Purified nCRP
(3.13–100 ng/ml) was used to construct standard curves. Bound CRP
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FIG. 2. Pairs of mutagenic oligonucleotides used in constructing CRP mutants. The sequences were designed based on the published sequence for WT CRP (33). Triplet codons of the mutated amino
acids are boxed. Mutated bases are in bold.
was detected as in ELISA. In some experiments binding curves were
constructed by using serial dilutions of purified WT and mutant CRP,
covering the range from 1.56 to 200 ng/ml.
Fn Binding Assay—The binding of CRP to Fn was assessed under 2
conditions unless otherwise mentioned, pH 7.0 and 5.0, using previously published methods (18, 31) with some modifications. For the
assay at pH 5.0, CRP was dialyzed against TBS, pH 5.0, and tested for
Fn binding activity (in addition to ELISA and PCh binding) within 72 h.
Microtiter wells were coated with Fn (Sigma, F2006) at a concentration
of 2 g/ml in TBS, pH 7.0, overnight at room temperature. Wells were
blocked with TBS containing 0.1% BSA. The binding curves were constructed using serial dilutions of purified WT and mutant CRP, covering the concentration range from 0.156 to 10 g/ml in either buffer A
(TBS, pH 7.0, 0.01% Tween 20) or buffer B (TBS, pH 5.0, 0.01% Tween
20) with and without 5 mM CaCl2. After a 3-h incubation at room
temperature, the wells were washed with buffer A. Affinity-purified
polyclonal rabbit anti-CRP antibody (1 g/ml) was used as a reporter to
detect bound CRP. The reporter antibody was purified from the antiCRP antibody (Sigma) by affinity chromatography on a CRP-conjugated
agarose column prepared by using the AminoLink Immobilization kit
(Pierce). Wells were developed with horseradish peroxidase-conjugated
goat anti-rabbit IgG H⫹L (Pierce) as in ELISA.
Polycation Binding Assay—Binding activity of CRP for polycationic
ligands was evaluated by two assays using poly-L-arginine (Sigma,
P-3892, Mr 70,000 –150,000) and poly-L-lysine (Sigma, P8920, Mr
150,000 –300,000, 0.01% solution). Microtiter wells were coated with
either poly-L-arginine (10 g/ml) or poly-L-lysine (0.002%) in TBS overnight at 4 °C. After blocking the wells with TBS containing 0.5% gelatin, purified WT and mutant CRP that were serially diluted (1.56 –100
ng/ml) in TBS containing 0.1% gelatin and 0.01% Tween 20 were added
to the wells and incubated overnight at 4 °C. Bound CRP was detected
as in ELISA.
Gel Filtration—Gel filtration analyses of purified WT and mutant
CRP dialyzed against pH 5.0 buffer was carried out on a Superose12
column (GE Healthcare) using the Biologic Duo Flow Protein Purification System (Bio-Rad). Affinity-purified CRP preparations (250 l, ⬃10
g depending upon the concentrations of the stocks) were injected into
the column and eluted with TBS at a flow rate of 200 l/min. Sixty
fractions (300 l each) were collected, and CRP-containing fractions
were located by ELISA. Purified nCRP at pH 7.0 was used to determine
the elution volume for the pentameric CRP.
Ca2⫹-Site Proteolytic Cleavage Assay—The Ca2⫹-binding sitedependent proteolytic cleavage assay of CRP was conducted as described previously (26) with modifications. WT and mutant CRP (4 g)
in TBS (pH 7.0 or 5.0) were incubated with 1 g of protease (from
Streptococcus griseus, Sigma, P6911) with and without 5 mM CaCl2 for
2 h at 37 °C. Digestion mix was then incubated with 20 l of packed
volume of anti-CRP-Sepharose beads for 1 h at 37 °C to separate CRP
from the enzyme. The conjugation of affinity-purified polyclonal antiCRP antibody to Sepharose was performed using the AminoLink Im-
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FIG. 3. Binding of CRP to PnC. Microtiter wells were coated with
PnC. Culture media containing various CRP species were diluted to
⬃50 ng/ml in TBS-Ca buffer and added to the wells. Bound CRP was
detected using the anti-CRP mAb HD2.4 as reporter. Values on the x
axis represent the ratio of the concentration of CRP measured by the
PnC binding assay over that measured by ELISA run in parallel using
nCRP to generate standard curves in both assays.
mobilization kit (Pierce). The beads were then washed with TBS, resuspended in TBS, and subjected to SDS-PAGE on a 4 –20%
polyacrylamide gradient gel under reducing conditions. The gels were
stained with silver stain (Bio-Rad). The Bio-Rad broad-range marker
was used as the molecular weight standard.
RESULTS

Construction, Expression, and Purification of Mutant CRP—
Ten CRP cDNAs encoding E138A, Q139A, D140A, E147A,
E147Q, E147K, Q150A, D60A, N61A, and the double mutant
D60A/E147A were constructed. Expression was determined by
ELISA performed on the culture supernatants of transfected
COS cells. Despite repeated transfections using duplicate
clones, under a wide variety of experimental conditions the
CRP mutants Q139A, D140A, and N61A were not expressed at
all and could not be pursued further. Expression levels of CRP
mutants E138A and Q150A were low (range, 5–100 ng/ml),
enough to test their PCh binding activity but not enough to test
their Fn binding activity. The other five CRP mutants involving Glu-147 and Asp-60 were successfully expressed, and their
expression levels (1000 –3000 ng/ml) were similar to that of the
WT recombinant CRP.
To determine the effect of mutating the Ca2⫹-site on the
binding of CRP to PCh and to design a purification strategy for
the expressed proteins, PCh binding assays using PnC and
PCh-BSA were performed on culture media containing WT and
mutant CRP. Data from the PnC assays are presented (Fig. 3);
PCh-BSA gave similar results. Values shown reflect the avidity
of individual CRP species for PCh relative to nCRP, whose PCh
binding activity was taken as unity. WT and the five CRP
mutants that were equally expressed bound to PCh efficiently.
Because binding of CRP to PCh requires binding of Ca2⫹ to
CRP first, these data indicated that the mutation of a single
amino acid, Glu-147 or Asp-60, did not affect the binding of
CRP to Ca2⫹. The binding of E138A CRP to PCh was reduced
by more than half compared with WT CRP. The Q150A CRP
failed to bind to PCh. The mutants E138A and Q150A were not
analyzed further. CRP mutants with substituted Glu-147 and
Asp-60 could be purified by PCh chromatography for further
characterization.
Binding of CRP to Fn—As shown in Fig. 4A, nCRP bound to
Fn at pH 7.0 in a dose-dependent manner. In the presence of 5
mM CaCl2, the binding was inhibited throughout the CRP doseresponse. At pH 7.0, inhibition of the binding of CRP (10 g/ml)
to Fn was dependent on the concentration of Ca2⫹ (Fig. 4B),
with maximum inhibition at ⬃2 mM CaCl2. Although 2 mM
CaCl2 was sufficient to inhibit binding of CRP to Fn, 5 mM

CaCl2 was chosen for subsequent experiments to ensure that
Ca2⫹ was in excess. The binding of various purified CRP mutants to Fn at pH 7.0 was evaluated next (Fig. 4C). Mutations
of Asp-60 to Ala and of Glu-147 to Ala/Gln resulted in a 70 –95%
decrease in the binding of CRP to Fn compared with that of WT
CRP. The decrease was most pronounced when Glu-147 was
substituted with Lys or when both residues were mutated
to Ala.
Because maximal binding of CRP to Fn occurs at pH 5.0 (18),
we tested the binding of CRP mutants to Fn at pH 5.0 (Fig. 4D).
Again, the binding of CRP mutants E147K and D60A/E147A to
Fn was reduced by 80 –90 and 50 – 60% respectively, and this
decrease was observed throughout the dose-response. Unlike at
pH 7.0, D60A, E147A, and E147Q CRP mutants efficiently
bound to Fn at pH 5.0. We, therefore, determined the effects of
Ca2⫹ on the binding of these CRP mutants to Fn at pH 5.0 (Fig.
4E). For clarity, the results are shown only for the WT CRP and
two mutants, E147A and D60A. To our surprise Ca2⫹ did not
inhibit the binding of mutant CRP to Fn at pH 5.0 and did not
even inhibit the binding of nCRP to Fn at pH 5.0. Binding of
other mutants to Fn at pH 5.0 was also not inhibited by Ca2⫹
(data not shown). These results clearly indicate that the inhibition of CRP-Fn interaction by Ca2⫹ occurs only at pH 7.0 and
not at pH 5.0. Next, we determined the inhibition of the binding
of CRP to Fn by Ca2⫹ at pH values varying from 4.0 to 7.0 (Fig.
4F). The binding of CRP to Fn was inhibited about 70% at pH
7.0, as before. Unexpectedly, the binding was inhibited by only
10% at pH 6.5, and no inhibition was observed at pH 6.0
and lower.
Assessment of the Overall Structure of CRP—We investigated the possibility that dialysis of CRP against TBS, pH 5.0,
might have perturbed the overall structure of CRP. Although
the ELISA performed on CRP at pH 5.0 indicated that CRP
retained its reactivity toward the mAb, 3 more assays were
utilized; PnC binding assay (Fig. 5A), gel filtration (Fig. 5B),
and Ca2⫹-site-dependent proteolytic cleavage assay (Fig. 5C).
WT and all mutant CRP bound to PnC in a dose-dependent
manner and produced essentially overlapping curves, indicating that their PCh binding activities were retained at pH 5.0.
Gel filtration to assess pentameric nature of the dialyzed mutant CRP showed that the elution volume of all CRP mutants at
pH 5.0 was similar to that of nCRP at pH 7.0. Data are shown
only for 3 mutants at pH 5.0; elution profiles of nCRP and other
mutants at pH 5.0 were identical. Last, at both pH 7.0 and 5.0,
in the absence of Ca2⫹, nCRP was cleaved by the protease,
generating 3 fragments as reported previously (26), and at both
pH values, Ca2⫹ protected CRP from proteolytic cleavage. Combined results indicated that the overall structure of CRP was
not altered at pH 5.0.
Binding of CRP to Polycations—To evaluate whether the
Ca2⫹ site binds only Fn or it binds, in general, to all Ca2⫹independent ligands of CRP, an assay was set up to determine
binding of CRP to polycations. We expected that the Fn site and
the polycation site on CRP would be the same since Ca2⫹ was
also found to inhibit CRP-polycation interaction (34). Substitution of Glu-147 with Lys and the double mutation of Asp-60/
Glu-147 to Ala abolished the binding of CRP to poly-L-arginine
(Fig. 6A). Although D60A CRP bound polycations and the binding of E147A and E147Q to the two polycations was different
(Fig. 6B), the results indicated that the Ca2⫹ site did participate in the binding of CRP to its Ca2⫹-independent ligands
including Fn and polycations.
Effect of Ca2⫹ Site Mutations on the Proteolytic Cleavage of
CRP—As a result of mutating Asp-60 and Glu-147, we discovered a loss of Fn binding activity and polycation binding activity but not of PCh binding (and, thus, not of Ca2⫹ binding)

Mechanism of CRP-Fibronectin Interactions in Vivo
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FIG. 4. Binding of CRP to Fn. Microtiter wells were coated with Fn. A, increasing concentrations of purified nCRP in TBS, pH 7.0, with and
without 5 mM CaCl2 were added to the wells. B, nCRP, 10 g/ml in TBS, pH 7.0, containing increasing concentrations of CaCl2 were added to the
wells. Binding of CRP to Fn in the absence of CaCl2 was taken as 100% to calculate percent inhibition. C, increasing concentrations of purified WT
and mutant CRP in TBS, pH 7.0, without CaCl2 were added to the wells. D, increasing concentrations of purified WT and mutant CRP in TBS,
pH 5.0, without CaCl2 were added to the wells. E, increasing concentrations of purified WT and mutant CRP in TBS, pH 5.0, with and without
CaCl2 were added to the wells. F, increasing concentrations of purified nCRP, 10 g/ml in TBS at increasing pH, with and without Ca2⫹ were added
to the wells. The binding of CRP to Fn in the absence of Ca2⫹ at various pH was plotted as 100%. In all, bound CRP was detected by using polyclonal
anti-CRP antibody as the reporter. All experiments were performed at least three times, and a representative experiment is shown.

FIG. 5. Effect of pH 5.0 on the overall structure of CRP. A, binding of purified WT and mutant CRP, dialyzed against TBS, pH 5.0, to PnC.
Microtiter wells were coated with PnC. Increasing concentrations of various CRP species in a TBS-Ca were added to the wells. Bound CRP was
detected by HD2.4 mAb. A representative of two experiments is shown. B, elution profiles of purified nCRP at pH 7.0 and purified mutant CRP
dialyzed against TBS, pH 5.0, from the Superose12 gel filtration column. C, Ca2⫹ site-dependent proteolytic cleavage of CRP. Purified nCRP at pH
7.0 and 5.0 was subjected to proteolytic cleavage in the absence and presence of Ca2⫹. A representative of 2–3 experiments is shown.

activity. This indicated that the structure of the Ca2⫹ site of
Ca2⫹-bound nCRP was different from that of Ca2⫹-bound mutant CRP. To support this conclusion, we examined the topology of Ca2⫹ site by protease cleavage assay (Fig. 7). Protease
treatment of nCRP in the absence of Ca2⫹ generated three
fragments (lane 3). The fragments designated A1 and A2 were
found to be of 17 and 16 kDa, and fragment B was estimated to
be of 6 kDa, consistent with the previous reports (26). nCRP
was completely protected from digestion in the presence of
Ca2⫹ (lane 4). The E147A CRP was cleaved in the absence of
Ca2⫹, generating only two fragments (lane 6), and in the presence of Ca2⫹, cleavage was not protected; instead all three
fragments were produced (lane 7). The D60A CRP was not

susceptible to protease at all (lanes 9 and 10). The effect of
mutating Asp-60 was not apparent in the cleavage of the double mutant (lanes 12 and 13). These data confirmed that the
configuration of the Ca2⫹ site of Ca2⫹-bound mutants was
different from that of Ca2⫹-bound nCRP.
DISCUSSION

CRP circulates in the body in its Ca2⫹-bound form, and Ca2⫹
inhibits binding of CRP to Fn. Therefore, the occurrence of
CRP-Fn interactions in vivo has been uncertain. We investigated the Fn-binding site on CRP and the mechanism of binding of CRP to Fn to determine the conditions for possible
interaction between Ca2⫹-bound CRP and Fn. Our major find-
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FIG. 6. Binding of CRP to polycations. Microtiter wells were
coated with either poly-L-arginine (A) or poly-L-lysine (B). Increasing
concentrations of purified WT and mutant CRP were added to the wells.
Bound CRP was detected by HD2.4 mAb. A representative of two
experiments is shown.

FIG. 7. Ca2ⴙ site-dependent proteolytic cleavage of CRP. Reducing SDS-PAGE of WT and mutant CRP treated with protease in the
absence and presence of Ca2⫹ was run on a 4 –20% polyacrylamide
gradient gel. Bands were visualized by silver staining. Before electrophoresis, all CRP samples were incubated with anti-CRP-conjugated
agarose beads to remove the protease from CRP. Molecular weight
markers are shown in lane 1.

ings were as follows. 1) Ca2⫹ inhibited binding of CRP to Fn at
pH 7.0 but not at pH 6.5 and lower. No inhibition was seen at
pH 5.0, the pH demonstrated for the maximal binding of CRP
to Fn. 2) The Ca2⫹ site of CRP participated in binding to Fn,
and the same site was found to be the polycation-binding site.
3) Mutations of Asp-60 or Glu-147 at the Ca2⫹ site of CRP
abolished Fn binding at pH 7.0 but not at pH 5.0. 4) Mutations
of Asp-60 or Glu-147 did not abolish PCh binding and Ca2⫹
binding. 5) Substitution of Asp-60 with Ala conferred resistance to CRP against proteolytic cleavage. 6) CRP, at a pH as
low as 5.0, retained its pentameric form, ability to bind Ca2⫹
and PCh, reactivity with a mAb, and susceptibility toward
the protease.
Based on the expression levels of CRP mutants, 7 amino
acids forming the Ca2⫹ site can be divided into two groups;
group 1 with Asp-60 and Glu-147 and group 2 with Asn-61,
Glu-138, Gln-139, Asp-140, and Gln-150. CRP mutants of
group 1 residues were expressed and bound PCh, reflecting
their binding to Ca2⫹ also. CRP mutants of group 2 residues
were either not expressed or poorly expressed with the loss of

Ca2⫹ binding and PCh binding ability. These results indicated
that the group 2 residues were critical for binding to Ca2⫹ and
for maintaining the native structure of CRP. Expression pattern of various CRP mutants favor the notion that binding of
Ca2⫹ to CRP occurs during its biosynthesis and is a prerequisite for the correct folding and assembly of the protein, and
perhaps this may be a general phenomenon for other Ca2⫹binding proteins.
The inability of group 2 CRP mutants to be expressed was
not surprising in view of the crystallographic data on Ca2⫹bound CRP (23–25). Each CRP subunit binds 2 Ca2⫹, Ca2⫹-1
and Ca2⫹-2. Ca2⫹-1 is co-ordinated by Asp-60, Asn-61, Glu-138,
Gln-139, and Asp-140. Asp-60 provides only one oxygen ligand
to Ca2⫹-1. Ca2⫹-2 is co-ordinated by Glu-138, Asp-140, Glu147, and Gln-150. In the crystal packing, CRP was still bound
to one Ca2⫹ when Glu-147 was not co-ordinated to Ca2⫹-2 but
was co-ordinated to Phe-66 from the neighboring pentamer.
Thus, Asn-61, Glu-138, Gln-139, Asp-140, and Gln-150 are
involved more than Asp-60 and Glu-147 in co-ordinating Ca2⫹.
Analyses of group 1 CRP mutants, D60A and E147A, were
sufficient to provide data to support the hypothesis that the
Ca2⫹ site of CRP participated in binding not only to Fn but also
to polycations (31, 35). The loss of Fn binding activity of these
CRP mutants at pH 7.0 suggested that the amino acids in CRP
that coordinated Ca2⫹ were also required for binding to Fn. On
the other hand, it was unlikely that these 2 amino acids were
the contact residues because their mutations did not abolish
binding of CRP to Fn at pH 5.0. Loss of binding of CRP to Fn at
pH 7.0 due to these mutations could be due to a change in the
disposition of the Ca2⫹ binding loop in the mutant CRP. This
conclusion is supported by the data showing altered susceptibility of these mutants to proteolytic cleavage.
The definition of the Fn-binding site of CRP can be derived
from the observed effects of acidic pH on CRP-Fn interaction.
Although we did not find a difference in the Ca2⫹ site of CRP at
pH 7.0 versus 5.0 using PCh binding and proteolytic cleavage
assays, a pH 6.3-dependent conformational change in CRP has
been shown previously by circular dichroism and fluorescence
spectra analyses (36). Assuming that the pH lower than 6.0
results in the loss of binding of one Ca2⫹ per CRP subunit,
creating half of the Ca2⫹ site vacant, and that Fn utilizes that
portion of the Ca2⫹ site to bind, then CRP can bind to PCh and
to Fn despite mutations of Asp-60 and Glu-147. It is not known
whether two Ca2⫹ per CRP subunit is an absolute necessity for
CRP-PCh interaction. The finding that the CRP-Fn interaction
is inhibited in a dose-dependent manner by relatively higher
concentrations of Ca2⫹ at pH 7.0 also supports that the vacancy
of entire Ca2⫹ site is not required for binding to Fn. The
Fn-binding site may also include the hydrophobic pocket located adjacent to the PCh-binding site of CRP (23–25). We
hypothesize that the Fn-binding site of CRP is composed of the
Ca2⫹ site occupied with only one Ca2⫹, and formation of such a
site is the consequence of low pH-induced conformational
change in and around the Ca2⫹ site. A similar proposal involving a conformational change has been proposed for the binding
of Fn to vascular endothelial growth factor whose binding to Fn
also increases at acidic pH (37).
We propose that the inhibition of binding of CRP to Fn by
Ca2⫹ at physiological pH serves as a mechanism to prevent
CRP-Fn interaction in the ECM of normal tissues. The Ca2⫹bound CRP gains the capacity to interact with Fn, exclusively
at the ECM of the inflammatory sites. One characteristic feature of the inflammatory sites, also of the tumors, is local
acidosis, resulting in a pH that can be as low as 5.8 (36, 38). The
architecture of the ECM in tumors is different from normal
tissues. Possible CRP-Fn interaction at the ECM of tumor sites
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is relevant because both Fn (28) and CRP (39 – 41) are present
at tumor sites. Recently, a polymeric form of Fn has been
shown to have antitumor properties (42). The ability of CRP to
convert Fn into polymeric Fn is not known, but CRP may
modify the ECM around the tumors to look it more like ECM of
normal tissues. CRP, monomeric CRP and the CRP-derived
peptides, all have been shown to inhibit tumor metastases in
experimental models of cancer (9, 43, 44). Involvement of Fn in
these in vivo antitumor actions of CRP is yet to be discovered,
but while investigating the regulation of CRP-Fn interaction by
pH, we made an unexpected observation that the denatured
CRP bound Fn more avidly than pentameric CRP did.2 These
findings strongly raise the possibility that CRP-Fn interaction
might play a role in modulating the progression of cancer.
All studies on CRP-Fn interaction so far have utilized
plasma Fn representing ECM Fn. However, under inflammatory conditions there are many alternatively spliced forms of
Fn expressed at various other sites in vivo (45). For example, in
atherosclerotic lesions, alternatively spliced Fn have been
found (46) in addition to the deposition of CRP at such lesions
(3, 4). Alternatively spliced forms of Fn are also expressed on
activated T lymphocytes (47), and interestingly, CRP binds to
activated T lymphocytes (48). We do not know if the mechanisms we report here for the interaction between CRP and
plasma Fn would be the same for the interaction between CRP
and alternatively spliced forms of Fn. It is a possibility that
Ca2⫹-bound CRP might interact with alternatively spliced
forms of Fn even at physiological pH. Existence of low pH at
tumor ECM and expression of Fn at sites other than ECM such
as atherosclerotic lesions and the T lymphocytes provide opportunity to investigate the functions of CRP-Fn complexes.
In summary, the interaction of circulating Ca2⫹-bound CRP
with Fn is controlled by pH. In normal physiological conditions,
binding of Ca2⫹ to CRP prevents interaction with Fn at the
ECM. At the ECM of the inflammatory sites with low pH, such
as in tumors, Ca2⫹-bound CRP gains the capability to interact
with Fn. Because CRP, Fn, and the ECM all have been implicated in cancer, we propose that CRP-Fn interactions may
change the architecture of ECM to modify the course of the
disease progression.
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